Related Experiment Video
Updated: Apr 17, 2026
Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
Bisoprolol vs. Carvedilol After Percutaneous Coronary Intervention in Acute Myocardial Infarction With Reduced Left
Jun-Chang Jeong1, Jong-Il Park1, Kang-Un Choi1
1Division of Cardiology, Yeungnam University Medical Center.
Insights
Bisoprolol and carvedilol demonstrated similar 3-year cardiovascular outcomes for patients with acute myocardial infarction and reduced ejection fraction after percutaneous coronary intervention. Both beta-blockers are suitable for secondary prevention in this high-risk group.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Outcomes Research
Background:
- Beta-blocker therapy is crucial for managing acute myocardial infarction (AMI) with reduced left ventricular ejection fraction (LVEF).
- Limited evidence exists comparing clinical outcomes among different beta-blocker types in this patient population.
- This study focuses on comparing bisoprolol and carvedilol in AMI patients with reduced LVEF post-percutaneous coronary intervention (PCI).
Purpose of the Study:
- To compare the 3-year cardiovascular outcomes between bisoprolol and carvedilol.
- To evaluate the efficacy of bisoprolol versus carvedilol in secondary prevention after AMI with reduced LVEF and PCI.
Main Methods:
- Utilized data from the Korean Acute Myocardial Infarction Registry V (KAMIR-V).
- Included 1,062 patients with AMI and reduced LVEF who underwent PCI and received either bisoprolol or carvedilol at discharge.
- Assessed the 3-year patient-oriented composite endpoint (POCE) including all-cause death, myocardial infarction, or revascularization.
Main Results:
- No significant difference in 3-year POCE was observed between bisoprolol (18.9%) and carvedilol (16.3%) groups (HR 0.79; 95% CI 0.54-1.17; P=0.237).
- Propensity score matching analysis yielded consistent results, showing comparable outcomes (HR 0.88; 95% CI 0.62-1.24; P=0.470).
Conclusions:
- Bisoprolol and carvedilol exhibit comparable 3-year cardiovascular outcomes in patients with AMI and reduced LVEF undergoing PCI.
- Both beta-blockers are suitable therapeutic options for secondary prevention in this high-risk cardiovascular patient group.
Background:
Beta-blocker therapy remains a cornerstone in the management of acute myocardial infarction (AMI) with reduced left ventricular ejection fraction (LVEF). However, evidence comparing clinical outcomes among different β-blocker types is limited. This study compared the 3-year cardiovascular outcomes between bisoprolol and carvedilol in patients with AMI and reduced LVEF who underwent percutaneous coronary intervention (PCI).
Methods And Results:
Data were derived from the Korean Acute Myocardial Infarction Registry V (KAMIR-V), a prospective nationwide multicenter registry. Among 16,521 enrolled patients, those who did not undergo PCI, had non-reduced or unknown LVEF, were not prescribed β-blockers, or received other β-blocker types were excluded. In all, 1,062 patients were classified according to the β-blocker prescribed at discharge (bisoprolol, n=386; carvedilol, n=676). The primary endpoint was the 3-year patient-oriented composite endpoint (POCE) of all-cause death, any myocardial infarction, or any revascularization. During a median follow-up of 1,076 days (interquartile range 732-1,109 days), POCE occurred in 18.9% of the bisoprolol group and 16.3% of the carvedilol group (hazard ratio [HR] 0.79; 95% confidence interval [CI] 0.54-1.17; P=0.237). After propensity score matching, results were consistent (HR 0.88; 95% CI 0.62-1.24; P=0.470).
Conclusions:
Among patients with AMI and reduced LVEF undergoing PCI, bisoprolol and carvedilol showed comparable 3-year cardiovascular outcomes. Both agents appear to be suitable options for secondary prevention in this high-risk population.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:22Heart Failure Drugs: β-Blockers
01:27Coronary Artery Disease V: Interprofessional Care
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System